Plain-English translation of NCT06800339 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment approach for advanced non-small cell lung cancer that may be surgically removable. You would receive three doses of focused radiation therapy (called stereotactic body radiation therapy), followed by combined with an immunotherapy drug called over about 9 weeks. After this treatment, your doctors will evaluate whether surgery is possible to remove any remaining cancer.
Current standard treatment for this type of lung cancer doesn't always work well enough, and some patients aren't able to have surgery. Researchers believe that adding focused radiation before the and immunotherapy may help shrink tumors more effectively and make surgery more possible, while also helping your immune system fight the cancer better.
You likely qualify if…
You likely don't qualify if…
You would first have your case reviewed by a team of lung cancer specialists to confirm you're a good candidate. Then you would receive three doses of focused radiation therapy over three days (every other day). About one week later, you would start infusions combined with , given once every three weeks for up to nine weeks total. During and after treatment, you'll have regular visits to monitor for side effects and check your response. About 100 days after your last dose, you would be evaluated to see if surgery is possible. After that, you would continue with standard follow-up care with your doctors.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States